Free Trial

Synaptogenix (SNPX) Competitors

Synaptogenix logo
$7.12 -1.08 (-13.17%)
As of 07/9/2025

SNPX vs. EGRX, GRCE, XCUR, ACRV, ARTV, ELYM, MRSN, BRNS, STTK, and ITRM

Should you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Eagle Pharmaceuticals (EGRX), Grace Therapeutics (GRCE), Exicure (XCUR), Acrivon Therapeutics (ACRV), Artiva Biotherapeutics (ARTV), Eliem Therapeutics (ELYM), Mersana Therapeutics (MRSN), Barinthus Biotherapeutics (BRNS), Shattuck Labs (STTK), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry.

Synaptogenix vs. Its Competitors

Synaptogenix (NASDAQ:SNPX) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Eagle Pharmaceuticals' return on equity of 0.00% beat Synaptogenix's return on equity.

Company Net Margins Return on Equity Return on Assets
SynaptogenixN/A -115.28% -58.31%
Eagle Pharmaceuticals N/A N/A N/A

In the previous week, Synaptogenix and Synaptogenix both had 1 articles in the media. Synaptogenix's average media sentiment score of 1.87 beat Eagle Pharmaceuticals' score of 0.00 indicating that Synaptogenix is being referred to more favorably in the media.

Company Overall Sentiment
Synaptogenix Very Positive
Eagle Pharmaceuticals Neutral

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Synaptogenix has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Eagle Pharmaceuticals has higher revenue and earnings than Synaptogenix.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SynaptogenixN/AN/A-$12.77M-$10.08-0.71
Eagle Pharmaceuticals$257.55M0.18$35.64MN/AN/A

Summary

Eagle Pharmaceuticals beats Synaptogenix on 6 of the 8 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SNPX vs. The Competition

MetricSynaptogenixMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.90M$2.99B$5.61B$9.11B
Dividend YieldN/A2.39%5.24%4.01%
P/E Ratio-0.717.5819.7619.92
Price / SalesN/A292.00430.8999.65
Price / CashN/A42.8637.4658.16
Price / Book1.647.638.045.49
Net Income-$12.77M-$55.05M$3.18B$250.27M
7 Day Performance-16.24%8.54%3.72%4.78%
1 Month Performance39.88%5.38%3.72%7.20%
1 Year Performance63.30%2.35%29.92%17.27%

Synaptogenix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SNPX
Synaptogenix
0.0459 of 5 stars
$7.12
-13.2%
N/A+66.0%$9.90MN/A-0.714Positive News
Gap Down
EGRX
Eagle Pharmaceuticals
2.608 of 5 stars
$3.25
+8.3%
N/A-41.2%$42.21M$257.55M0.00100News Coverage
GRCE
Grace Therapeutics
2.5783 of 5 stars
$3.04
+1.3%
$12.00
+294.7%
N/A$41.49MN/A-3.42N/AHigh Trading Volume
XCUR
Exicure
1.5476 of 5 stars
$6.95
+7.4%
N/A+2,279.1%$40.88M$500K-1.8250Positive News
Gap Down
ACRV
Acrivon Therapeutics
3.4406 of 5 stars
$1.31
+4.8%
$17.71
+1,252.2%
-81.1%$39.19MN/A-0.5958Positive News
ARTV
Artiva Biotherapeutics
3.0649 of 5 stars
$1.69
+7.0%
$17.80
+953.3%
N/A$38.49M$250K0.0081
ELYM
Eliem Therapeutics
N/A$1.28
+1.6%
N/A-81.2%$38.08MN/A-2.429
MRSN
Mersana Therapeutics
4.0477 of 5 stars
$0.33
+7.5%
$5.20
+1,490.2%
-80.6%$37.92M$40.50M-0.55150Gap Up
BRNS
Barinthus Biotherapeutics
2.9983 of 5 stars
$0.99
+6.2%
$6.25
+534.5%
-26.1%$37.41M$14.97M-0.60107Positive News
STTK
Shattuck Labs
3.7419 of 5 stars
$0.81
+4.8%
$7.50
+826.6%
-79.1%$36.98M$5.72M-0.58100Positive News
ITRM
Iterum Therapeutics
2.0046 of 5 stars
$0.93
+1.0%
$9.00
+864.6%
-26.5%$36.95MN/A-0.9410

Related Companies and Tools


This page (NASDAQ:SNPX) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners